AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Air Industries Group Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Stoke Therapeutics, Inc. (Nasdaq: STOK) filed a Form 8-K on July 10, 2025 under Item 7.01 (Regulation FD). The filing states that the company issued a press release (Exhibit 99.1) announcing the presentation of data from an analysis that informed the design of the planned Phase 3 EMPEROR study and evaluated the potential effects of the proposed zorevunersen dosing regimen. No financial metrics, study results, or timelines were included in the 8-K. The information is furnished (not filed) and therefore is not incorporated by reference into other Exchange Act or Securities Act filings unless specifically stated.

Stoke Therapeutics, Inc. (Nasdaq: STOK) ha presentato un modulo 8-K il 10 luglio 2025 ai sensi della voce 7.01 (Regolamento FD). Nel documento si comunica che la società ha rilasciato un comunicato stampa (Allegato 99.1) in cui annuncia la presentazione dei dati di un'analisi che ha guidato la progettazione dello studio di Fase 3 EMPEROR pianificato e ha valutato i potenziali effetti del regime posologico proposto per zorevunersen. Nel modulo 8-K non sono stati inclusi dati finanziari, risultati dello studio o tempistiche. Le informazioni sono fornite (e non depositate) e pertanto non sono incorporate per riferimento in altri documenti ai sensi dell'Exchange Act o del Securities Act, salvo diversa indicazione.

Stoke Therapeutics, Inc. (Nasdaq: STOK) presentó un Formulario 8-K el 10 de julio de 2025 bajo el ítem 7.01 (Regulación FD). El documento indica que la compañía emitió un comunicado de prensa (Exhibición 99.1) anunciando la presentación de datos de un análisis que informó el diseño del estudio de Fase 3 EMPEROR planeado y evaluó los posibles efectos del régimen de dosificación propuesto para zorevunersen. No se incluyeron métricas financieras, resultados del estudio ni cronogramas en el 8-K. La información se proporciona (no se presenta formalmente) y, por lo tanto, no se incorpora por referencia en otros documentos bajo la Exchange Act o Securities Act, a menos que se indique específicamente.

Stoke Therapeutics, Inc. (나스ë‹�: STOK)ëŠ� 2025ë…� 7ì›� 10ì� 항목 7.01(Regulation FD)ì—� ë”°ë¼ Form 8-Kë¥� 제출했습니다. 제출 문서ì—는 회사가 ë³´ì¡° 문서 99.1ë¡� ë³´ì´ëŠ� ë³´ë„ìžë£Œë¥� 발표했으ë©�, ì´ëŠ” 계íšë� 3ìƒ� EMPEROR 연구 설계ë¥� 알리ëŠ� ë¶„ì„ ë°ì´í„°ì™€ 제안ë� zorevunersen 투여 요법ì� 잠재ì � ì˜í–¥ì� í‰ê°€í•� ë‚´ìš©ìž„ì„ ëª…ì‹œí•˜ê³  있습니다. 8-Kì—는 재무 ì§€í‘�, 연구 ê²°ê³¼ ë˜ëŠ” ì¼ì •ì� í¬í•¨ë˜ì§€ 않았습니ë‹�. ì� ì •ë³´ëŠ� 제출ë� ê²ƒì´ ì•„ë‹Œ 제공ë� 정보로서, 특별íž� 명시ë˜ì§€ 않는 í•� 다른 Exchange Act ë˜ëŠ” Securities Act 문서ì—� 참조ë¡� í¬í•¨ë˜ì§€ 않습니다.

Stoke Therapeutics, Inc. (Nasdaq : STOK) a déposé un formulaire 8-K le 10 juillet 2025 sous l'item 7.01 (Règlement FD). Le dépôt indique que la société a publié un communiqué de presse (Exhibit 99.1) annonçant la présentation de données issues d'une analyse qui a orienté la conception de l'étude de phase 3 EMPEROR prévue et évalué les effets potentiels du schéma posologique proposé pour le zorevunersen. Aucun indicateur financier, résultat d'étude ou calendrier n’a été inclus dans le 8-K. Les informations sont fournies (et non déposées) et ne sont donc pas incorporées par référence dans d'autres dépôts relevant de l'Exchange Act ou du Securities Act, sauf indication contraire explicite.

Stoke Therapeutics, Inc. (Nasdaq: STOK) reichte am 10. Juli 2025 ein Formular 8-K unter Punkt 7.01 (Regulation FD) ein. Die Einreichung besagt, dass das Unternehmen eine Pressemitteilung (Anlage 99.1) veröffentlicht hat, in der die Präsentation von Daten aus einer Analyse angekündigt wird, die das Design der geplanten Phase-3-EMPEROR-Studie informierte und die potenziellen Auswirkungen des vorgeschlagenen Dosierungsschemas für Zorevunersen bewertete. Finanzkennzahlen, Studienergebnisse oder Zeitpläne wurden im 8-K nicht enthalten. Die Informationen werden bereitgestellt (nicht eingereicht) und sind daher nicht in andere Einreichungen nach dem Exchange Act oder Securities Act durch Verweis aufgenommen, sofern nicht ausdrücklich angegeben.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine Reg FD update; provides visibility on Phase 3 planning but lacks efficacy or financial data.

The 8-K simply notifies investors that Stoke has released supportive data used to shape its upcoming Phase 3 EMPEROR trial of zorevunersen. Because the document omits the data itself, it offers limited incremental insight into clinical risk or valuation. The disclosure is furnished under Item 7.01, signalling that management views it as informational rather than materially transformative. Absent study results or new guidance, I classify the immediate market impact as neutral.

Stoke Therapeutics, Inc. (Nasdaq: STOK) ha presentato un modulo 8-K il 10 luglio 2025 ai sensi della voce 7.01 (Regolamento FD). Nel documento si comunica che la società ha rilasciato un comunicato stampa (Allegato 99.1) in cui annuncia la presentazione dei dati di un'analisi che ha guidato la progettazione dello studio di Fase 3 EMPEROR pianificato e ha valutato i potenziali effetti del regime posologico proposto per zorevunersen. Nel modulo 8-K non sono stati inclusi dati finanziari, risultati dello studio o tempistiche. Le informazioni sono fornite (e non depositate) e pertanto non sono incorporate per riferimento in altri documenti ai sensi dell'Exchange Act o del Securities Act, salvo diversa indicazione.

Stoke Therapeutics, Inc. (Nasdaq: STOK) presentó un Formulario 8-K el 10 de julio de 2025 bajo el ítem 7.01 (Regulación FD). El documento indica que la compañía emitió un comunicado de prensa (Exhibición 99.1) anunciando la presentación de datos de un análisis que informó el diseño del estudio de Fase 3 EMPEROR planeado y evaluó los posibles efectos del régimen de dosificación propuesto para zorevunersen. No se incluyeron métricas financieras, resultados del estudio ni cronogramas en el 8-K. La información se proporciona (no se presenta formalmente) y, por lo tanto, no se incorpora por referencia en otros documentos bajo la Exchange Act o Securities Act, a menos que se indique específicamente.

Stoke Therapeutics, Inc. (나스ë‹�: STOK)ëŠ� 2025ë…� 7ì›� 10ì� 항목 7.01(Regulation FD)ì—� ë”°ë¼ Form 8-Kë¥� 제출했습니다. 제출 문서ì—는 회사가 ë³´ì¡° 문서 99.1ë¡� ë³´ì´ëŠ� ë³´ë„ìžë£Œë¥� 발표했으ë©�, ì´ëŠ” 계íšë� 3ìƒ� EMPEROR 연구 설계ë¥� 알리ëŠ� ë¶„ì„ ë°ì´í„°ì™€ 제안ë� zorevunersen 투여 요법ì� 잠재ì � ì˜í–¥ì� í‰ê°€í•� ë‚´ìš©ìž„ì„ ëª…ì‹œí•˜ê³  있습니다. 8-Kì—는 재무 ì§€í‘�, 연구 ê²°ê³¼ ë˜ëŠ” ì¼ì •ì� í¬í•¨ë˜ì§€ 않았습니ë‹�. ì� ì •ë³´ëŠ� 제출ë� ê²ƒì´ ì•„ë‹Œ 제공ë� 정보로서, 특별íž� 명시ë˜ì§€ 않는 í•� 다른 Exchange Act ë˜ëŠ” Securities Act 문서ì—� 참조ë¡� í¬í•¨ë˜ì§€ 않습니다.

Stoke Therapeutics, Inc. (Nasdaq : STOK) a déposé un formulaire 8-K le 10 juillet 2025 sous l'item 7.01 (Règlement FD). Le dépôt indique que la société a publié un communiqué de presse (Exhibit 99.1) annonçant la présentation de données issues d'une analyse qui a orienté la conception de l'étude de phase 3 EMPEROR prévue et évalué les effets potentiels du schéma posologique proposé pour le zorevunersen. Aucun indicateur financier, résultat d'étude ou calendrier n’a été inclus dans le 8-K. Les informations sont fournies (et non déposées) et ne sont donc pas incorporées par référence dans d'autres dépôts relevant de l'Exchange Act ou du Securities Act, sauf indication contraire explicite.

Stoke Therapeutics, Inc. (Nasdaq: STOK) reichte am 10. Juli 2025 ein Formular 8-K unter Punkt 7.01 (Regulation FD) ein. Die Einreichung besagt, dass das Unternehmen eine Pressemitteilung (Anlage 99.1) veröffentlicht hat, in der die Präsentation von Daten aus einer Analyse angekündigt wird, die das Design der geplanten Phase-3-EMPEROR-Studie informierte und die potenziellen Auswirkungen des vorgeschlagenen Dosierungsschemas für Zorevunersen bewertete. Finanzkennzahlen, Studienergebnisse oder Zeitpläne wurden im 8-K nicht enthalten. Die Informationen werden bereitgestellt (nicht eingereicht) und sind daher nicht in andere Einreichungen nach dem Exchange Act oder Securities Act durch Verweis aufgenommen, sofern nicht ausdrücklich angegeben.

false 0001009891 0001009891 2025-07-10 2025-07-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): July 10, 2025

 

AIR INDUSTRIES GROUP

(Exact Name of Registrant as Specified in its Charter)

 

Nevada   001-35927   80-0948413
State of Incorporation   Commission File Number   IRS Employer I.D. Number

 

1460 Fifth Avenue, Bay Shore, New York 11706

(Address of Principal Executive Offices)

 

Registrant’s telephone number: (631) 968-5000

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001   ARI   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

  

Item 7.01 Regulation FD Disclosure 

On July 10, 2025, Air Industries Group (“Air Industries” or the “Company”) issued a press release announcing that it has received a contract worth $5.4 million for landing gear assemblies for the US Air Force B-52 aircraft. Deliveries under the contract are expected to begin in late 2026 and continue through the third quarter of 2027. The order results from the Company’s increased focus on after-market spares and is the first order from a new customer.

 

The information in this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed as “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of such Section, nor shall it be deemed incorporated by reference in any filing by Air Industries under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Text of press release issued July 10, 2025, by Air Industries Group.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

  

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: July 10, 2025

 

  AIR INDUSTRIES GROUP
     
  By: /s/ Scott Glassman
    Scott Glassman
    Chief Financial Officer

 

 

FAQ

What did Stoke Therapeutics (STOK) announce in its July 10, 2025 Form 8-K?

The company furnished a press release describing data that influenced the design of its Phase 3 EMPEROR study and zorevunersen dosing regimen.

Does the 8-K include actual results from the Phase 3 EMPEROR study?

No. The filing only notes that data informing the study design were presented; specific results are not included.

Is the information in Exhibit 99.1 considered "filed" with the SEC?

No. The company states that the press release is "furnished" under Item 7.01 and is not deemed "filed" under Section 18 of the Exchange Act.

Were any financial statements or earnings figures provided in this 8-K?

No financial statements, revenue figures, or earnings data were included.

What is the trading symbol and exchange listing for Stoke Therapeutics?

Stoke Therapeutics' common stock trades on the Nasdaq Global Select Market under the symbol STOK.
Air Industries

NYSE:AIRI

AIRI Rankings

AIRI Latest News

AIRI Latest SEC Filings

AIRI Stock Data

12.31M
2.87M
27.2%
7.42%
0.96%
Aerospace & Defense
Aircraft Parts & Auxiliary Equipment, Nec
United States
BAY SHORE